Search | Page 30 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. TCRαβ+/CD19+ Depleted Haploidentical HSCT + Zoledronate

    ... transplantation with a haploidentical donor peripheral blood stem cell graft depleted of TCRαβ+ cells and CD19+ cells in conjunction with the ...

    Clinical Trial last updated 04/29/2016 - 4:35pm.

  2. Allogeneic Transplantation Using Timed Sequential Busulfan, Cladribine, and Fludarabine Conditioning in Patients With Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)

    ... with fludarabine and cladribine before a stem cell transplant in patients with AML or MDS may help to control the ...

    Clinical Trial last updated 04/28/2016 - 3:41pm.

  3. Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation

    ... Purpose:  Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative therapy for patients ... mortality (NRM), but recent advances utilizing post-transplant cyclophosphamide (PT-Cy) have revolutionized haplo-HCT and ... Stem cell transplant Drug: Azacitidine Other Names: Vidaza Ladakamycin ...

    Clinical Trial last updated 05/03/2016 - 11:15am.

  4. Detection of Recurrent Mutations by Pooled Targeted Next-Generation Sequencing in MDS Patients Prior to Treatment with Hypomethylating Agents or Stem Cell Transplantation

    ... and decitabine. The 76 patients in Cohort 2 underwent a stem cell transplant . The researchers focused on 74 genes, including all ...

    Research Review last updated 05/02/2016 - 9:26am.

  5. Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant

    ... of improvement (relapsed), previously treated with donor stem cell transplant . Biological therapies, such as cellular adoptive immunotherapy, ...

    Clinical Trial last updated 04/29/2016 - 10:34am.

  6. RIC Transplant Using Haplo Donors

    ... -mismatched first-degree relatives utilizing PBSC as the stem cell source. The primary objective of the study is to estimate the incidence of ...

    Clinical Trial last updated 04/29/2016 - 10:52am.

  7. Myelodysplastic syndromes: What do hospitalists need to know?

    ... is a misconception that anemia (a low red blood cell count) is normal in the elderly and that a workup is not warranted in ... decitabine (Dacogen®), intensive chemotherapy, and stem cell transplantation.  Patients tend to tolerate azacitidine and ...

    Research Review last updated 05/02/2016 - 9:21am.

  8. Pilot Study of Lupron to Improve Immune Function After Allogeneic Bone Marrow Transplantation

    ... of the blood and immune system is to give a patient stem cells from the bone marrow of a donor whose genes are very ... system to recover in a way that improves white blood cell function. In this study they will be looking at the drug lupron, a ...

    Clinical Trial last updated 04/28/2016 - 11:14am.

  9. Incidence and Burden of the Myelodysplastic Syndromes

    ... costs and require more hospital services.  -Red-blood cell transfusion dependence is associated with increased mortality and worse ... be considered for a clinical trial or allogeneic stem cell transplant if available.  This is a large unmet need in MDS.  ...

    Research Review last updated 05/02/2016 - 9:11am.

  10. Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant

    ... side effects and best dose of selinexor when given after stem cell transplant in treating patients with acute myeloid leukemia that is at ...

    Clinical Trial last updated 04/29/2016 - 10:38am.